Can-Fite BioPharma Updates Namodenoson Patent Status
Ticker: CANF · Form: 6-K · Filed: Jul 29, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: patent, pharmaceutical, update
TL;DR
Can-Fite BioPharma is fighting to extend Namodenoson patent protection.
AI Summary
On July 29, 2024, Can-Fite BioPharma Ltd. issued a press release providing an update on its Namodenoson patent. The company is seeking to extend the patent protection for Namodenoson, a drug candidate for liver diseases and cancer.
Why It Matters
This update is crucial for Can-Fite BioPharma as it relates to the potential for extended market exclusivity for their drug candidate, Namodenoson, impacting future revenue streams.
Risk Assessment
Risk Level: medium — Patent extensions are complex and not guaranteed, creating uncertainty for the drug's future market exclusivity and commercialization.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant
- Namodenoson (drug_candidate) — Subject of patent update
- July 29, 2024 (date) — Date of press release
FAQ
What is the specific nature of the Namodenoson patent update?
The press release, dated July 29, 2024, provides an update on the patent status of Namodenoson.
What is Namodenoson?
Namodenoson is a drug candidate developed by Can-Fite BioPharma Ltd. for liver diseases and cancer.
What is the purpose of this filing?
This is a Form 6-K filing by Can-Fite BioPharma Ltd. to report a press release concerning its Namodenoson patent.
When was the press release issued?
The press release was issued on July 29, 2024.
What is Can-Fite BioPharma Ltd.'s primary business?
Can-Fite BioPharma Ltd. is involved in the pharmaceutical preparations industry, as indicated by its SIC code [2834].
Filing Stats: 183 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-07-29 07:03:27
Filing Documents
- ea0210157-6k_canfite.htm (6-K) — 9KB
- ea021015701ex99-1_canfite.htm (EX-99.1) — 11KB
- 0001013762-24-001791.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: July 29, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2